Porton Biopharma Limited (PBL) is a manufacturer and developer of biopharmaceutical products ranging from next-generation vaccines to cancer treatments.
Based in the UK, the company specialises in progressing drug products from initial concept and research and development (R&D), through the various stages of scale-up and process development to manufactured product at pilot-scale. This includes product characterisation, analytical method development, stability studies and process troubleshooting.
PBL provides manufacturing services for both native and recombinant therapeutic proteins. The company offers a high level of documentation, demonstrating process and product consistency.
PBL has extensive experience in the development, manufacturing and commercialisation of biopharmaceutical products, as well as analytical support such as protein analysis and enzymology.
The company presents microbial product manufacturers with a flexible service that translates research methods into repeatable production processes. Products are well-characterised and of high-quality.
PBL provides a wide range of product development services, including characterisation, analytical development, process troubleshooting and technology transfer.
PBL offers production services for a wide range of clinical materials, including low-volume, high-potency and toxic bacterial products. Development fermentation studies are offered in a range of production platforms, including Wave-bag™ and stirred tank bioreactors from <1l bench-top fermenters through to fermentation suites with four 15l and one 50l vessel for parallel development and scale-up. Cell harvesting by batch, continuous centrifugation and tangential flow filtration are also available.
PBL also performs translational development to help biopharmaceutical products progress to good manufacturing practice (GMP) manufacturing. It leverages the experience of having its own products on the market.
PBL’s biopharmaceutical products include the UK’s anthrax vaccine and a therapeutic treatment for acute lymphoblastic leukaemia (ALL) Erwinase®, which is licensed in 20 locations worldwide. The company’s state-of-the-art current GMP (cGMP) facilities are licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA), Pharmaceuticals and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA).
PBL performs analytical services and process redevelopment to optimise production. Options include the introduction of disposable technology to process modification, as well as method analysis and quantification. These services ensure that techniques are fit-for-purpose using the expert knowledge of PBL’s regulatory and validation teams.
The company’s development group designs and adapts analytical techniques to demonstrate process reproducibility and product quality.
In addition, PBL works closely with start-up biotech firms and mid/large pharmaceutical organisations worldwide to offer manufacturing process troubleshooting. The company finds the root cause of any issues and implements tried and tested solutions. This vigilant service reduces production costs with reduced downtime.
Commercialised out of Public Health England on 1 April 2015, PBL provides development and manufacturing services for life-saving products.
The company uses extensive biopharmaceutical experience to produce biologics and perform characterisation and analytical validation. Products meet regulatory requirements, which PBL fully understands from licensing its own products.
To find out how PBL can help you move your research from the bench to the clinic, please contact them via the enquiry box.
Porton Biopharma Limited
Manor Farm Road
Wiltshire, SP4 0JG
Tel: +44 198 061 2100